Crestor vs Repatha: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Work?

Rosuvastatin and evolocumab both lower LDL cholesterol, but through entirely different mechanisms. Rosuvastatin blocks the enzyme HMG-CoA reductase inside liver cells, reducing cholesterol synthesis and upregulating LDL receptors. Evolocumab binds and inactivates PCSK9, the protein that degrades those same LDL receptors, so more receptors survive to clear LDL from circulation. The result is additive: combining them produces LDL reductions that neither drug achieves alone.

Rosuvastatin's Mechanism in Brief

Statins lower intracellular cholesterol, which signals the liver to express more LDL receptors on the cell surface. Rosuvastatin is among the most potent statins available, with a hydrophilic structure that limits muscle uptake and a long 19-hour half-life that supports once-daily dosing FDA label, NDA 021366.

Evolocumab's Mechanism in Brief

PCSK9 normally tags LDL receptors for destruction after each LDL particle is internalized. By blocking PCSK9, evolocumab allows LDL receptors to recycle approximately three to four times per cycle instead of being degraded. This mechanism is independent of statin use, which is why the two agents work so well together. The FDA approval for evolocumab covers both primary hyperlipidemia and established cardiovascular disease.

LDL-C Efficacy: How Much Does Each Drug Actually Lower?

Rosuvastatin 40 mg lowers LDL-C by roughly 55% from baseline as monotherapy. Evolocumab 140 mg every two weeks reduces LDL-C by approximately 59% on top of whatever statin dose is already being used. In patients already on high-intensity statin therapy, the combination frequently brings LDL-C below 30 mg/dL.

Rosuvastatin Dose-Response Data

The dose-response relationship for rosuvastatin is well characterized. At 5 mg, expect a 35 to 40% LDL-C reduction. At 10 mg, roughly 43%. At 20 mg, around 48%. At 40 mg (the maximum approved dose in the U.S.), approximately 55% JUPITER baseline characteristics, NEJM 2008. Patients who cannot tolerate 40 mg daily often achieve 43 to 48% reduction at 20 mg, which still satisfies the ACC/AHA definition of high-intensity statin therapy.

Evolocumab Efficacy Across Populations

In the FOURIER trial, patients on background statin therapy with a mean baseline LDL-C of 92 mg/dL reached a median on-treatment LDL-C of 30 mg/dL with evolocumab 140 mg Q2W, a 59% reduction FOURIER, NEJM 2017. The PROFICIO program pooled 4,465 patients across Phase 3 studies and found mean LDL-C reductions of 57 to 61% depending on background therapy, with 87% of patients reaching an LDL-C <70 mg/dL PROFICIO data, JACC 2016.

Real-World LDL Reductions vs Trial Results

Real-world registries typically show slightly smaller effects than trials due to adherence gaps. A 2020 analysis of the HEYMANS registry (N=3,802 patients on evolocumab in European clinical practice) found mean LDL-C reductions of 54% after 12 months, compared with the 59% seen in FOURIER HEYMANS registry, Atherosclerosis 2020. For rosuvastatin, a 2019 retrospective cohort study in the U.S. Optum database (N=148,000+) found 46% mean LDL-C reduction at 40 mg, slightly below the 55% seen in controlled trials, attributable to intermittent adherence JAHA 2019.

Cardiovascular Outcomes: What Do the Landmark Trials Actually Show?

LDL-C reduction is a surrogate endpoint. The question that matters clinically is whether these drugs reduce heart attacks, strokes, and cardiovascular death. Both have large randomized controlled trials showing hard outcome benefits, but the trial designs are different enough that direct comparison requires care.

JUPITER: Rosuvastatin in Primary Prevention

JUPITER (Justification for the Use of Statins in Prevention) enrolled 17,802 apparently healthy adults with LDL-C <130 mg/dL but elevated hsCRP (>2.0 mg/L). Rosuvastatin 20 mg daily vs placebo reduced the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) over a median follow-up of 1.9 years JUPITER, NEJM 2008. The trial was stopped early by the data safety monitoring board. Number needed to treat to prevent one primary endpoint event was 25 over 4 years.

The trial authors wrote: "Rosuvastatin significantly reduced the incidence of major cardiovascular events" in a population that traditional risk calculators would have classified as low-to-intermediate risk, expanding the statin indication meaningfully.

FOURIER: Evolocumab Added to Statin Therapy

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease already on optimized statin therapy (mean LDL-C 92 mg/dL at baseline). Adding evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) over a median follow-up of 2.2 years FOURIER, NEJM 2017. The key secondary endpoint (cardiovascular death, MI, or stroke) was reduced by 20% (HR 0.80, 95% CI 0.73 to 0.88).

The principal investigator Marc Sabatine stated: "Each 1 mmol/L (38.7 mg/dL) reduction in LDL-C with evolocumab reduced the risk of major cardiovascular events by approximately 19%," consistent with the cholesterol-lowering hypothesis regardless of baseline or mechanism.

What Real-World Outcomes Data Add

Randomized trial populations are selected and protocol-managed. Real-world data from the ACC's PINNACLE registry and from Danish national registers provide a more representative picture. A 2022 analysis of 11,400 Danish patients who initiated PCSK9 inhibitor therapy (primarily evolocumab) after a myocardial infarction found a 22% lower risk of recurrent MI compared with matched statin-intensification controls over 3.5 years of follow-up JAHA 2022. Those real-world patients had higher baseline comorbidity burdens than FOURIER participants, making the finding clinically meaningful for the population actually seen in practice.

Safety Profiles: Tolerability in the Real World

The safety profiles of rosuvastatin and evolocumab differ substantially, which is part of what makes them complementary rather than competitive in high-risk patients.

Rosuvastatin Safety

Statin-associated muscle symptoms (SAMS) are the most clinically significant tolerability issue. Myalgia without CK elevation occurs in approximately 5 to 10% of statin-treated patients in observational studies, though the SAMSON trial (N=200, BMJ 2020) used an n-of-1 design and found that 90% of reported statin symptoms were not pharmacologically caused by the statin SAMSON, NEJM 2020. Rhabdomyolysis is rare, occurring in fewer than 1 per 10,000 patient-years at standard doses. Rosuvastatin carries a small risk of new-onset diabetes: a 2010 meta-analysis in The Lancet (N=91,140) found an odds ratio of 1.09 per statin vs placebo, translating to approximately 1 extra case of diabetes per 255 patients treated for 4 years Sattar et al, Lancet 2010.

Hepatotoxicity sufficient to require drug discontinuation occurs in <0.1% of patients. Routine liver enzyme monitoring is no longer recommended by the FDA for patients on statins FDA Safety Communication 2012.

Evolocumab Safety

Evolocumab's safety record across FOURIER and the open-label OSLER studies is reassuring. Injection-site reactions occurred in 2.1% of evolocumab patients vs 1.6% of placebo patients. Neurocognitive events (confusion, memory impairment) were initially a concern when PCSK9 inhibitors were first approved; the EBBINGHAUS sub-study of FOURIER (N=1,974) found no difference in cognitive composite scores between evolocumab and placebo over 19 months EBBINGHAUS, NEJM 2017. New-onset diabetes rates were no higher than placebo, which is a meaningful advantage over statins in patients already at diabetes risk.

Muscle enzyme elevations occurred in 4.8% of evolocumab patients and 4.7% of placebo patients in FOURIER, confirming that evolocumab does not cause myopathy at a rate above background FOURIER, NEJM 2017.

Cost, Access, and Adherence: The Practical Gap Between Trials and Practice

Efficacy data from controlled trials becomes irrelevant if patients cannot afford or access the drug. The cost differential between rosuvastatin and evolocumab is large enough to affect prescribing decisions at every income level.

Cost Comparison

Generic rosuvastatin costs under $10 per month at most major U.S. Pharmacies. Brand-name Crestor carries a higher price, but generic availability since 2016 has made rosuvastatin one of the least expensive high-intensity statin options. Evolocumab (Repatha) has a list price of approximately $5,800 per year (roughly $484/month) as of 2024, though net prices after rebates are lower. Amgen's patient-assistance program (Repatha SupportPlus) covers patients with incomes under 600% of the federal poverty level and those facing high out-of-pocket costs, but navigating the program adds administrative burden for both patients and prescribers.

Insurance Prior Authorization Burden

In a 2021 analysis of commercial insurance claims, 71% of PCSK9 inhibitor prescriptions required prior authorization, and 14% were ultimately abandoned at the pharmacy due to coverage denial or cost JAMA Cardiology 2021. That 14% abandonment rate is not a trivial number when the patients most likely to be prescribed evolocumab are those with the highest cardiovascular risk.

Adherence Data

One-year persistence with evolocumab in real-world U.S. Claims data is approximately 40 to 55%, compared with 60 to 70% for high-intensity statins in the same populations Am J Manag Care 2020. The injection-based administration of evolocumab contributes to this gap; some patients find biweekly self-injection less convenient than a daily oral tablet regardless of efficacy.

Who Should Switch from Crestor to Repatha?

Switching entirely from rosuvastatin to evolocumab is rarely the right move. The more common clinical scenario is adding evolocumab to existing statin therapy when LDL-C remains above goal despite maximally tolerated statin dosing.

ACC/AHA 2022 Guideline Criteria for Adding a PCSK9 Inhibitor

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction identifies four populations where adding a PCSK9 inhibitor is reasonable after statin therapy ACC/AHA 2022 Guideline:

• Very high-risk ASCVD patients with LDL-C >70 mg/dL despite maximally tolerated statin plus ezetimibe
• Patients with heterozygous familial hypercholesterolemia (HeFH) with LDL-C >100 mg/dL on maximally tolerated therapy
• Patients with a 10-year ASCVD risk >20% who cannot achieve <70 mg/dL with oral agents alone
• Statin-intolerant patients (confirmed by rechallenge) who need substantial LDL-C lowering for primary or secondary prevention

The guidelines specify that a "statin-first" approach still applies, meaning evolocumab is approved as add-on or replacement in true statin intolerance, not as a first-line substitution for convenience.

When Monotherapy with Evolocumab Is Appropriate

For patients with confirmed, rechallenged statin intolerance (defined by the EISD score or documented adverse reactions to at least two different statins at the lowest available dose), evolocumab monotherapy is a legitimate option. In this scenario, evolocumab 140 mg Q2W as monotherapy lowered LDL-C by 55% from baseline in the GAUSS-3 trial (N=511), where patients had documented statin intolerance GAUSS-3, JAMA 2016.

A Practical Decision Framework

Use this three-step clinical check before switching or adding:

1. Confirm the patient is on the maximum tolerated rosuvastatin dose (5 mg to 40 mg depending on tolerance) plus ezetimibe 10 mg daily before escalating.
2. Recheck a fasting lipid panel 6 to 8 weeks after optimizing oral therapy. If LDL-C remains >70 mg/dL in a very-high-risk patient, escalation to evolocumab is guideline-supported.
3. Verify insurance coverage and patient eligibility for Amgen's SupportPlus program before writing the prescription, because a denied claim is clinically equivalent to no prescription at all.

Real-World Evidence Summary: What Registries and Claims Data Tell Us

Randomized trials optimize for internal validity. Real-world evidence fills the external validity gap by capturing the messier, comorbid populations that clinicians actually treat.

Registry Evidence for Rosuvastatin

The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA), while using atorvastatin rather than rosuvastatin, established the template for statin real-world benefit in hypertensive patients with <3 cardiovascular risk factors. Rosuvastatin-specific registry data from the DYSIS-II study (N=3,031, 18 countries, European Heart Journal 2016) found that only 18% of very-high-risk patients on statin therapy achieved an LDL-C <70 mg/dL, highlighting the treatment gap that evolocumab was designed to address DYSIS-II, EHJ 2016.

Registry Evidence for Evolocumab

The HEYMANS registry tracked 3,802 patients across 11 European countries who initiated evolocumab in routine clinical practice. At 12 months, 68% of patients reached an LDL-C <70 mg/dL, compared with the trial-based 87% figure from PROFICIO HEYMANS registry, Atherosclerosis 2020. The 19-percentage-point gap reflects real-world adherence variability. Patients who remained adherent to biweekly injections showed efficacy nearly identical to FOURIER trial participants.

What the Data Gap Means Clinically

A 19-point adherence-driven efficacy gap is not a drug failure. It is a prescribing and support failure. Clinicians who pair evolocumab prescriptions with structured adherence support (nurse follow-up calls, autoinjector training, 90-day supply dispensing) recover much of that gap. In the OSLER-1 open-label extension (N=1,324), 12-month persistence was 86% when patients had structured support versus 54% in unstructured real-world comparators OSLER-1, NEJM 2015.

Combination Therapy: Rosuvastatin Plus Evolocumab as the Standard of Care for Very High Risk

For patients with established ASCVD, the question is no longer rosuvastatin or evolocumab. The 2022 ACC/AHA guidelines, the European Society of Cardiology 2021 dyslipidemia guidelines, and the National Lipid Association all support combination therapy as the standard approach when LDL-C remains above 55 to 70 mg/dL after maximally tolerated statin therapy.

LDL-C Targets in Very-High-Risk Patients

The ACC/AHA 2022 guideline recommends an LDL-C target of <70 mg/dL for very-high-risk patients (two or more major ASCVD events, or one major event plus multiple high-risk conditions) and considers <55 mg/dL a reasonable goal for those at even higher risk ACC/AHA 2022. Rosuvastatin 40 mg alone brings a typical patient from a starting LDL-C of 130 mg/dL to approximately 59 mg/dL, which barely achieves the <70 mg/dL target. Adding evolocumab to that regimen brings the same patient to approximately 24 mg/dL, which is well below the <55 mg/dL threshold.

Residual Risk Reduction from Adding Evolocumab to Statin

FOURIER's subgroup analyses showed that the absolute risk reduction from evolocumab was largest in patients with longer follow-up and in those who had the highest baseline LDL-C on statin therapy. In patients followed for the full 2.2-year median, the number needed to treat to prevent one primary endpoint event was 67 FOURIER, NEJM 2017. Extended follow-up data from the FOURIER-OLE open-label extension (ESC 2022, N=6,635) found that longer-duration evolocumab therapy reduced cardiovascular death by 23% compared with late-starters, supporting the concept that sustained LDL lowering amplifies benefit over time.